Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-1501 in Type 1 Diabetes Islet Transplant
NCT04711226Phase 2Withdrawn
- Sponsor
- Anelixis Therapeutics
- Start
- Feb 2021
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tegoprubart in type 1 diabetes mellitus (T1D), sponsored by Anelixis Therapeutics. Planned start Feb 2021; status: withdrawn.
02
Drugs
tegoprubart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04711226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711226.